Revolutionizing Adoptive Cell Therapy Development with Bruker's Beacon® Platform

Adoptive cell therapies (ACTs), such as CAR-T and TCR-T, hold immense promise for revolutionizing cancer treatment. However, their complex development processes often hinder their widespread adoption. A critical challenge lies in precisely characterizing individual cells within ACT populations to understand their therapeutic potential and identify optimal candidates.

Bruker's Beacon Platform introduces a transformative approach to single-cell analysis. By leveraging optofluidic technology, the Beacon enables researchers to delve into the functional intricacies of ACT cells at unprecedented depth. High-throughput experiments on thousands of individual cells provide unparalleled insights into cytotoxicity, cytokine secretion, and surface marker expression, revealing the heterogeneity within ACT populations and identifying potential biomarkers. The Beacon's NanoPen chambers and OptoSelect chips offer dynamic, live-cell monitoring, capturing the full spectrum of cellular behaviors. Unlike traditional bulk assays, which often mask critical variations, the Beacon's single-cell approach provides a clearer picture of ACT cell diversity.

By overcoming the limitations of traditional methods, the Beacon empowers researchers to unlock the full potential of ACTs. Access the application note below for an in-depth look at how this innovative approach to single-cell analysis is driving more precise and personalized cancer treatments.